Literature DB >> 25131415

Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population.

Steffen Leth1, Søren Jensen-Fangel, Lars Østergaard, Andreas Arendtsen Rostved, Bente Jespersen, Ole Schmeltz Søgaard.   

Abstract

BACKGROUND: Data on occurrence and risk factors for pneumocystis pneumonia (PCP) in patients with end-stage renal disease (ESRD) are sparse.
METHODS: This was a nationwide population-based study assessing occurrence and risk factors for PCP among patients with ESRD and population controls over a 21-year period (1/1 1990 to 31/12 2010). Using Danish registry data, first-time diagnoses of PCP were identified.
RESULTS: We identified 13 296 adult patients with ESRD and 244 255 controls, yielding 63 560 and 2 223 660 person-years of follow-up (PYFU), respectively. Fifty-eight first-time diagnoses of PCP were recorded in the ESRD group. Forty-six episodes occurred among renal transplant recipients (RTx) and 12 among haemodialysis patients (HD), yielding incidence rates of 181 (136-242) and 43.1 (24.5-75.9) per 100 000 PYFU. Compared to population controls, we found incidence rate-ratios of 125.9 (78.4-204) among RTx and 29.9 (14.1-59.7) among HD patients. Risk factors for PCP in RTx were age 50-65 years, age > 65 years, diabetes, polycystic kidney disease and hypertensive kidney disease/nephrosclerosis with an IRR of 2.22 (1.14-4.31), 3.12 (1.35-7.21), 3.44 (1.16-10.2), 4.25 (1.55-11.7) and 3.87 (1.49-10.0), respectively, and more than 36 months of dialysis before transplantation with an IRR of 1.99 (1.03-3.84). Among RTx the risk of PCP was highest during the first 6 months post-transplantation and increased from the beginning (IR1990-94 = 111 (46.3-267) per 100 000 PYFU) towards the end of the study period (IR2005-10 = 299 (203-439)).
CONCLUSION: The PCP risk is substantial in RTx within the first 6 months of transplantation, emphasizing the potential benefit of prophylactic treatment in the early post-transplant period. Importantly, we identified subgroups within the RTx group that require more attention.

Entities:  

Keywords:  End-stage renal disease; pneumocystis pneumonia; renal transplant recipients; risk factors

Mesh:

Year:  2014        PMID: 25131415     DOI: 10.3109/00365548.2014.936492

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.

Authors:  Jin-Hua Chen; Chi-Ching Chang; Hui-Ching Hsu; Yu-Sheng Chang; Tsung-Yun Hou; Lung-Fang Chen; Li-Fang Hu; Tzu-Min Lin; Chi-Sheng Chiou; Kai-Len Tsai; Sheng-Hong Lin; Pei-I Kuo; Wei-Sheng Chen; Yi-Chun Lin
Journal:  Clin Rheumatol       Date:  2021-03-01       Impact factor: 2.980

Review 2.  Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.

Authors:  Norihiko Goto; Kenta Futamura; Manabu Okada; Takayuki Yamamoto; Makoto Tsujita; Takahisa Hiramitsu; Shunji Narumi; Yoshihiko Watarai
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-11-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.